R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses

R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses

Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence

Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence

BIOPITCH, hosted at the annual Florida Innovation Conference, spotlights the state's most promising ventures ORLANDO, Fla., Dec. 9, 2024 /PRNewswire/

BIOPITCH, hosted at the annual Florida Innovation Conference, spotlights the state's most promising ventures ORLANDO, Fla., Dec. 9, 2024 /PRNewswire/

Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec.

Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec.

Data provide support for planned expanded clinical development of best-in-class RGT-61159 in MYB-dependent hematologic cancers, including AML Potent anti-tumor activity

Data provide support for planned expanded clinical development of best-in-class RGT-61159 in MYB-dependent hematologic cancers, including AML Potent anti-tumor activity